Patients 21 and 23 with meningioma CNS WHO grade 3 were also treated with everolimus followed by everolimus plus bevacizumab (patient 21), or everolimus alone (patient 23) due to mTOR pathway activation in Phospho-IHC for three/one and four months, respectively until tumor progression (Table 1, Fig. 3B) [53]. Here, MTOR is linked to meningioma.